The company said, "In 2023, the Company plans to: Achieve positive adjusted EBITDA results for the full year of 2023; grow total full-year 2023 revenue by at least 25% through continued adoption of lasers and consumables by the dental community including general dentists, dental specialists, dental hygienists, and group practice entities; Expand OEM revenue base through its partnership with EdgeEndo; Broaden participation in BIOLASE dental and hygiene academies to expand awareness of the benefits of BIOLASE lasers to patients; Launch training centers to enhance sales and marketing efforts and communicate the benefits of BIOLASE technology; Expand the Waterlase Exclusive Trial Program to drive increased adoption; Open a model dental office to increase marketing, testimonial, and training opportunities; Expand the DSO customer base and further penetrate the DSO market; Realize cost savings and improve quality from in-house manufacturing of key components; Execute growth strategy with over $13.0 million in cash and cash equivalents, including net proceeds from its January 2023 equity raise."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BIOL:
